1SXP — SCHOTT Pharma AG & Co KgaA Cashflow Statement
0.000.00%
- €3.00bn
- €3.04bn
- €957.09m
- 87
- 21
- 40
- 45
Annual cashflow statement for SCHOTT Pharma AG & Co KgaA, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 77.6 | 101 | 126 | 152 | 150 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.65 | 9.86 | 25 | -2.1 | -2.47 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.16 | -17 | -27.3 | -15.7 | 16.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 104 | 132 | 182 | 182 | 225 |
| Capital Expenditures | -85.3 | -98.6 | -153 | -176 | -145 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 4.09 | 2.73 | 10.6 | 4.11 | -0.633 |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -81.2 | -95.9 | -142 | -171 | -146 |
| Financing Cash Flow Items | -14.3 | -26 | -40.9 | 11 | -52 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -14.4 | -27.5 | -42.4 | -11.4 | -78.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.95 | 9.25 | 0.935 | -4.44 | -1.18 |